Share
COVID-19 mRNA vaccine technology transfer hub a boost for Africa
South Africa is in the thick of the third wave of the Covid-19 pandemic with government having tightened the lockdown to alert level 4. The country's vaccination programme has been described by many as slow. Joining CNBC Africa for more is Professor Richard Gordon from the South African Medical Research Council and Caryn Fenner, Technical Director at Afrigen Biologics.
Thu, 01 Jul 2021 17:04:47 GMT
Disclaimer: The following content is generated automatically by a GPT AI and may not be accurate. To verify the details, please watch the video
AI Generated Summary
- Africa's challenges in vaccine distribution and the need for regional cooperation
- The role of mRNA technology transfer hub in enhancing vaccine production capabilities in Africa
- The transformative impact of research and development in advancing vaccine technology and combating the pandemic
South Africa is currently battling with the third wave of the Covid-19 pandemic, prompting the government to tighten lockdown restrictions to alert level 4. The country's vaccination program has been criticized for being slow, with many pointing out the need for timely and efficient vaccination efforts. Joining CNBC Africa to discuss this pressing issue were Professor Richard Gordon from the South African Medical Research Council and Caryn Fenner, the Technical Director at Afrigen Biologics. The focus of the discussion was on the establishment of a COVID-19 mRNA vaccine technology transfer hub in Africa and its potential implications for speeding up the vaccination process. The conversation shed light on the challenges faced by African countries in accessing vaccines, the innovative potential of mRNA technology, and the role of research and development in combating the pandemic.
Professor Gordon highlighted the disparities in vaccine distribution, stating that Africa has been underserved in the global rollout of vaccines. He emphasized the need for closer collaboration between governments, regulators, manufacturers, and distributors to address supply chain issues and ensure efficient vaccine distribution across the continent. Additionally, he commended the South African government for its efforts in accelerating the vaccination program and emphasized the importance of regional cooperation in vaccine distribution.
On the other hand, Caryn Fenner discussed the role of the technology transfer hub in facilitating the production and distribution of mRNA vaccines in Africa. She explained that the hub aims to transfer technology to enable local manufacturing and enhance the capacity to respond to future pandemics. Fenner emphasized the versatility of mRNA technology, which allows for rapid adaptation to new variants and potential use in addressing other diseases prevalent in Africa.
The discussion also touched upon the significance of research and development in advancing vaccine technology. Professor Gordon highlighted the transformative impact of COVID-19 on medical innovation, citing the rapid development of mRNA-based vaccines as a groundbreaking achievement. He underscored the need for ongoing research to address the evolving nature of the pandemic and explore potential strategies for long-term vaccine production.
Looking ahead, both speakers expressed optimism about Africa's vaccine manufacturing capabilities and stressed the importance of regulatory cooperation in expediting vaccine deployment. They emphasized the need for national and regional coordination to streamline vaccine distribution processes and ensure equitable access to vaccines. Overall, the conversation highlighted the pivotal role of technology transfer, research, and regulatory mechanisms in advancing Africa's response to the COVID-19 pandemic.
SIGN UP FOR OUR NEWSLETTER
DAILY UPDATE
Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.